pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
122
stories
3h
Capricor investor calls for change as company awaits decision on Duchenne candidate
biospace
5h
Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths
biospace
7h
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
1d
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
2d
Amgen cans its TScan partnership; Amylyx reveals $350M offering
endpoints
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
Dissecting Chinese trial strategy in wake of deaths
stat
2d
Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
fiercebiotech
2d
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
3d
Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
fiercebiotech
3d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
4d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
7d
Capricor soars on potential FDA review extension, filing amendments
biospace
7d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
7d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
9d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
10d
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
10d
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
endpoints
11d
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
14d
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
14d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
16d
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
stat
16d
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
16d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
21d
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
21d
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
← prev
page 1 of 5
next →
